Bret Bogue, founder and president of Apothecary Genetics, has come up with 2 new strains that have tested remarkably high in CBDs. Cannaberry and Early Wave have tested as high as 20+ percent CBD and 7% THC.
“We have found that these strains work best with patients that are suffering from internal pain and inflammation. We’ve also done some testing that would indicate that these strains seem to produce an even higher CBD level when grown in higher altitudes. We believe that the cross between Early Wave and Catatonic and Catatonic X BlackBerry allows for these genetics to produce high CBD content. “
“It is our hope that someday we can turn these strains into oils and tinctures that will be able to be sold over the counter in years to come. For now, if you are interested in trying any of Apothecary Genetics high CBD strains, they are available online at ApothecaryGenetics.com or ApothecaryGenetics.co.uk.
We are hoping by putting these strains out that people will start to breed and come up with even higher CBD strains in the future. It has been our goal from the start of Apothecary to produce genetics that will enable further medical research and development of pharmaceutical grade cannabis.
We believe that for far too long, the cannabis industry has been held back by the pharmaceutical companies. It is up to the genetic companies of the world to start taking control of their own genetics and help develop the modern medicines that we will apply to the pharmaceutical industry.
In closing, we would hope with the new laws and progressive research that is going on, that the strains mentioned will be used for medications instead of using in conjunction with new developed chemo & radiation protocols to reduce the amount of treatments while increasing their dosage of cannabis.”